These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20869423)

  • 41. Human immunodeficiency virus infection and chronic myeloid leukemia.
    Patel M; Philip V; Fazel F; Lakha A; Vorog A; Ali N; Karstaedt A; Pather S
    Leuk Res; 2012 Nov; 36(11):1334-8. PubMed ID: 22867899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The tyrosine kinase inhibitor dasatinib reduces the growth of intracellular Mycobacterium tuberculosis despite impairing T-cell function.
    Wehrstedt S; Kubis J; Zimmermann A; Bruns H; Mayer D; Grieshober M; Stenger S
    Eur J Immunol; 2018 Nov; 48(11):1892-1903. PubMed ID: 30242834
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Breccia M; Colafigli G; Molica M; Alimena G
    Expert Opin Drug Saf; 2016; 15(4):525-33. PubMed ID: 26799331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Gong Z; Zheng L; Tang Z; Chen Z; Wang W; Bai S; Tang G; Medeiros LJ; Hu S
    Ann Hematol; 2017 Mar; 96(3):501-504. PubMed ID: 27915425
    [No Abstract]   [Full Text] [Related]  

  • 45. Lymphoproliferative Disorders in Patients with Chronic Myeloid Leukemia: A Single-Center Case Series.
    Alshehry NF; Al-Huneini M; Lipton JH; Michelis FV
    Acta Haematol; 2015; 134(3):161-7. PubMed ID: 25968918
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations.
    Reff MJ; Shillingburg A; Shah B; Elder C; Prescott H; Kennerly-Shah J
    J Oncol Pharm Pract; 2020 Jan; 26(1):156-174. PubMed ID: 31354102
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions.
    Hijiya N; Millot F; Suttorp M
    Pediatr Clin North Am; 2015 Feb; 62(1):107-19. PubMed ID: 25435115
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution of CML treatment.
    Kimura S
    Int J Hematol; 2021 May; 113(5):622-623. PubMed ID: 33721192
    [No Abstract]   [Full Text] [Related]  

  • 49. Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors.
    Bumm T; Deininger J; Newell AH; Lawce H; Olson S; Mauro M; Druker B; Deininger M
    Leukemia; 2010 Aug; 24(8):1525-1528. PubMed ID: 20535153
    [No Abstract]   [Full Text] [Related]  

  • 50. Tyrosine kinase inhibitor for CML: all the same?
    Veltmaat L; Cortes J
    Blood Adv; 2024 Oct; 8(20):5339-5341. PubMed ID: 39392647
    [No Abstract]   [Full Text] [Related]  

  • 51. Extranodal marginal zone lymphoma arising in a patient with chronic myelogenous leukemia on long-term tyrosine kinase inhibitors.
    Xu X; Hassan A
    Leuk Lymphoma; 2014 Mar; 55(3):715-7. PubMed ID: 23741976
    [No Abstract]   [Full Text] [Related]  

  • 52. [Update on tyrosine kinase inhibitor therapy for chronic myeloid leukemia and pregnancy].
    Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):66-8. PubMed ID: 22575200
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia.
    Wang W; Chen Z; Hu Z; Yin CC; Li S; Bai S; Bueso-Ramos CE; Medeiros LJ; Hu S
    Blood Cancer J; 2016 Nov; 6(11):e490. PubMed ID: 27813536
    [No Abstract]   [Full Text] [Related]  

  • 54. The DESTINY of chronic myeloid leukeamia.
    Abruzzese E
    Lancet Haematol; 2017 Jul; 4(7):e303-e304. PubMed ID: 28566210
    [No Abstract]   [Full Text] [Related]  

  • 55. [Management of chronic myeloid leukemia for Japanese patients in the era of TKIs].
    Usui N
    Rinsho Ketsueki; 2014 May; 55(5):497-507. PubMed ID: 24881914
    [No Abstract]   [Full Text] [Related]  

  • 56. [Efficacy of levocarnitine for tyrosine kinase inhibitor-induced painful muscle cramps in patients with chronic myelogenous leukemia].
    Yamada M; Kuroda H; Shimoyama S; Ito R; Sugama Y; Sato K; Yamauchi N; Horiguchi H; Nakamura H; Hamaguchi K; Abe T; Fujii S; Maeda M; Kato J
    Rinsho Ketsueki; 2016 Apr; 57(4):489-91. PubMed ID: 27169456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia?
    Cristóbal I; Manso R; González-Alonso P; Rojo F; García-Foncillas J
    Leukemia; 2015 Oct; 29(10):2117. PubMed ID: 26283451
    [No Abstract]   [Full Text] [Related]  

  • 58. Epidemiology of chronic myeloid leukaemia: an update.
    Höglund M; Sandin F; Simonsson B
    Ann Hematol; 2015 Apr; 94 Suppl 2():S241-7. PubMed ID: 25814090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival.
    Geelen IGP; Thielen N; Janssen JJWM; Hoogendoorn M; Roosma TJA; Willemsen SP; Valk PJM; Visser O; Cornelissen JJ; Westerweel PE
    Haematologica; 2017 Dec; 102(12):e486-e489. PubMed ID: 28860340
    [No Abstract]   [Full Text] [Related]  

  • 60. Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia.
    Sgherza N; Russo Rossi AV; Colonna P; Carluccio P; Delia M; Specchia G
    Int J Hematol; 2013 Oct; 98(4):483-6. PubMed ID: 23881644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.